The Role of Tyrosine Kinase Inhibitors in Unresectable Hepatocellular Carcinoma - Episode 6

Updates from IMbrave150, LEAP-002, and HIMALAYA Trials

Richard Finn, MD, and David James Pinato, MD, MRCP, PhD, provide an overview of the IMbrave150 study, the LEAP-002 trial, and the HIMALAYA trial, discussing how these trials have changed the treatment landscape for hepatocellular carcinoma.